SQZ Biotechnologies Co (SQZ Biotechnologies Co) Debt-to-EBITDA : -0.40 (As of Sep. 2023)

View and export this data going back to 2020. Start your Free Trial

What is SQZ Biotechnologies Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

SQZ Biotechnologies Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $2.40 Mil. SQZ Biotechnologies Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $19.08 Mil. SQZ Biotechnologies Co's annualized EBITDA for the quarter that ended in Sep. 2023 was $-53.42 Mil. SQZ Biotechnologies Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was -0.40.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for SQZ Biotechnologies Co's Debt-to-EBITDA or its related term are showing as below:

SQZB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.42 Med: -1.19 Max: -0.43
Current: -0.44

During the past 5 years, the highest Debt-to-EBITDA Ratio of SQZ Biotechnologies Co was -0.43. The lowest was -1.42. And the median was -1.19.

SQZB's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.375 vs SQZB: -0.44

SQZ Biotechnologies Co Debt-to-EBITDA Historical Data

The historical data trend for SQZ Biotechnologies Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQZ Biotechnologies Co Debt-to-EBITDA Chart

SQZ Biotechnologies Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-EBITDA

-1.42

-1.17

-1.21

-0.43

SQZ Biotechnologies Co Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial														-0.77	-1.19	-0.40	-0.38	-0.40

Competitive Comparison of SQZ Biotechnologies Co's Debt-to-EBITDA

For the Biotechnology subindustry, SQZ Biotechnologies Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SQZ Biotechnologies Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SQZ Biotechnologies Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where SQZ Biotechnologies Co's Debt-to-EBITDA falls into.

SQZ Biotechnologies Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

SQZ Biotechnologies Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(6.562	+	20.909)	/	-64.141
	=	-0.43

SQZ Biotechnologies Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.397	+	19.075)	/	-53.416
	=	-0.40

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2023) EBITDA data.

SQZ Biotechnologies Co (OTCPK:SQZB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

SQZ Biotechnologies Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of SQZ Biotechnologies Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

SQZ Biotechnologies Co (SQZ Biotechnologies Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SQZ Biotechnologies Co (OTCPK:SQZB) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

200 Arsenal Yards Boulevard, Suite 210, Watertown, MA, USA, 02472

Website

https://www.sqzbiotech.com

SQZ Biotechnologies Co is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ has the ability to deliver multiple materials into many patient cell types to engineer what it believes to be an unprecedented range of potential therapeutics for a range of diseases. The company has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and potentially improve the patient experience over existing cell therapy approaches, with accelerated production timelines under 24 hours and the elimination of preconditioning and lengthy hospital stays.

Executives

Richard Capasso	officer: See Remarks	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marshelle Smith Warren	officer: Chief Medical Officer	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Klavs F. Jensen	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Amy W Schulman	director, 10 percent owner	PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017
Bernard Coulie	director	C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Vink Patrick V.j.j.	director	ETZELSTRASSE 20, 8707 UETIKON AM SEE V8 V8
Temasek Holdings (private) Ltd	10 percent owner	60B ORCHARD ROAD #06-18 TOWER 2, THE ATRIUM@ORCHARD, SINGAPORE U0 238891
Invus Public Equities, L.p.	10 percent owner	C/O THE INVUS GROUP, LLC, 750 LEXINGTON AVENUE, 30TH FLOOR, NEW YORK NY 10022
American International Group, Inc.	10 percent owner	1271 AVE OF THE AMERICAS, FL 37, NEW YORK NY 10020-1304
Polaris Entrepreneurs' Fund Vii, L.p.	10 percent owner	ONE MARINA PARK DRIVE, 10TH FLOOR, BOSTON MA 02210
S.a. Westend	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Artal Group S.a.	10 percent owner	VALLEY PARK, 44, RUE DE LA VALLEE, LUXEMBOURG N4 L-2661
Arny Schulman, As Trustee The Armon R. Sharei Irrevocable Gst Trust Of 2016 U/d/t Dated December 29, 2016	10 percent owner	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Marc Elia	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Armon Sharei	director, officer: President and CEO	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472